# **Tuberculosis: 1. Introduction**

### Anne Fanning, MD

uberculosis (TB) has infected about one-third of the world's 5 billion people. In 1995, from this pool of infected people, about 3.3 million new active smear-positive cases were reported, along with an estimated 4 million other cases, which led to about 2–3 million deaths. Although TB rates in Canada are as low as almost anywhere in the world, many people from countries where rates are high — in whom previous TB and the attendant 5% to 10% risk of reactivation is likely — arrive in Canada each year: 250 000 as landed immigrants and another 2 million as visitors. TB is back on the agenda in Canada because, although diagnosis is simple and curative drugs have been available for 50 years, the disease has been all but forgotten. The capacity to establish and maintain a global system to control TB has been thwarted by poverty and homelessness and diminished by the spread of HIV infection. It is time to re-examine the issue of TB control in a Canadian context.

Annual rates of TB in Canada reached a plateau in about 1989 at levels slightly higher than those of The Netherlands and Scandinavia — 7 per 100 000 population per year. Such low rates suggest stability but in fact hide the continuing high rates in the aboriginal population (about 70 per 100 000 population), which contributes 15% of cases, 7 times the expected rate for that group. (The term aboriginal refers to Canadian First Nations people, living on or off reserves, with or without treaty status.) The decline continues in the Canadian-born nonaboriginal population, where rates are about 1 per 100 000, nearing 1 per million — the rate at which TB is considered eliminated. However, 60% of all cases of TB in Canada now occur in people born elsewhere, in countries where the TB epidemic continues unabated.

Because TB is fairly rare in Canada, with about 2000 cases annually, the average practitioner will see only one case in 10 years. Each of these represents a failure of the control system. TB is 99% curable and 90% preventable. The ability to control TB with modern chemotherapeutic drugs has been demonstrated in Canada's northern Inuit population; in 1950 the rate of new disease in this population was 25%, but by 1970 it was so low as to be almost unmeasurable. This situation illustrates what can be accomplished with an effective medical regimen, a concerted public health commitment and a willing community.<sup>3</sup>

Because there is little active case-finding for this disease, we depend on alert physicians who are aware of the high rates of TB in aboriginal, elderly and foreign-born people, and in people with suppressed immune systems. When TB is suspected, sputum microscopy and culture should be conducted immediately. There is a need for prompt communication among the practitioner, the laboratory and the public health system so that patients are appropriately treated and people who have come into contact with the infected person are assessed and offered prophylactic treatment.

DOTS (directly observed therapy, short course) is more than simply direct observation of treatment: it is a strategy for controlling TB that requires government commitment, an uninterrupted supply of free drugs and a network of laboratories for microscopy diagnosis, training and a good surveil-



#### Education

#### Éducation

Dr. Fanning is with the Prevention and Control Section, Communicable Disease Cluster, World Health Organization, Geneva, Switzerland

CMAJ 1999;160:837-9

Series editor: Dr. Anne Fanning, Medical Officer Training, Communicable Disease Prevention and Control, World Health Organization, Geneva, Switzerland

See pages 789, 799 and 821 for other articles on tuberculosis

Return to March 23, 1999 Table of Contents

Return to series list



lence system for outcome evaluation. The use of DOTS to control TB has been championed by the World Health Organization (WHO)<sup>4</sup> because it overcomes the problem of compliance with treatment. Even in Canada there are difficulties ensuring that patients comply with therapy. In fact, Canada is not able to report outcome of treatment to WHO and therefore is not considered a DOTS country.

In the past, Canada has helped developing countries to strengthen TB control programs.<sup>5</sup> This country has also been a leader in some of the earliest and most effective BCG (Bacille Calmette–Guérin vaccine) trials. The focus on TB control and its management varies among the Canadian provinces and territories, therefore contact information to obtain guidance in diagnosing and managing TB is listed below for each province and territory.

As public sector commitment to health care and education declines around the world, the need for privatesector nongovernmental organizations to get involved in TB control has become urgent. In the past, TB associations have rallied public support for TB control and have encouraged governments to adopt TB control programs to assure the public's health. Such vigour will be needed on a global scale to reverse the rising rates of tuberculosis.

The authors of this series of papers are among the leaders in TB control in Canada and worldwide. A discussion of the epidemiology of the disease in Canada will make practitioners aware of the patient populations that are most at risk. A review of the multisystem nature of the disease will focus on the most common pulmonary and extrapulmonary forms, as well as the presentation of TB in children and its atypical appearance in people with HIV infection. Although new tools for diagnosis are available, culture diagnosis, the gold standard, depends on a network of laboratories and reference centres; in Canada the existence of such networks is increasing, as will be seen in the discussion of the labora-

## Provincial tuberculosis control representatives

Disease Control and Epidemiology Newfoundland and Labrador Department of Health West Block, Confederation Building 1st floor, Higgins Line St John's NF A1B 4J6 Tel: 709 729-3430

Chief Health Officer
Department of Health & Social Services
PO Box 2000, 11 Kent Street
Charlottown PE C1A 7N8
Tel: 902 368-4996

Medical Officer of Health Public Health Services 3rd floor, Sunnyside Place 1600 Bedford Highway Bedford NS B4A 1E8 Tel: 902 424-8698

Health Promotion and Disease Prevention Department of Health and Community Services Public Health Management Services 2nd floor, 520 King Street PO Box 5100 Fredericton NB E3B 5G8

Tel: 506 453-3092

Programmes de contrôle de la tuberculose Maladies infectieuses Régie régionale de la santé et des services sociaux de Montréal-Centre Direction de la santé publique 3e étage, 1616 boul René-Levesque ouest Montreal QC H3H 1P8 Tel: 514 932-3055 x4492

Disease Control Service Public Health Branch Ontario Ministry of Health 8th floor, 5700 Yonge Street North York ON M2M 4K5 Tel: 416 327-7419

Tuberculosis Control
Office of Special Health Initiatives
Health Protection Branch,
Health Canada
Brooke Claxton Building
Tunney's Pasture,
Postal Locator: 0900B
Ottawa ON K1A 0L2
Tel: 613 941-1191

Director of TB Control Respiratory Hospital Room RS112, 810 Sherbrook Street Winnipeg MB R3A 1R8 Tel: 204 787-2338 Saskatchewan TB Control Program Royal University Hospital 5th floor, Ellis Hall 103 Hospital Drive Saskatoon SK SN7 0W6 Tel: 306 933-6347

Director, TB Services 23rd floor, 10025 Jasper Avenue Box 1360 Edmonton AB T5J 2N3 Tel: 403 422-2444

Division of TB Control BC Centre for Disease Control Society 655 West 12th Avenue Vancouver BC V5Z 4R4 Tel: 604 660-6102

TB Coordinator
Communicable Disease Control Unit
Health & Social Services
Yukon Territory Government
#4, Hospital Road
Whitehorse YT Y1A 3H8
Tel: 867 667-8371

Health Protection Unit Health & Social Services Government of NWT 5022 49th Street, Centre Square Mall Yellowknife NT X1A 2L9 Tel: 867 873-7721



tory aspects of TB. Articles on TB in aboriginal and immigrant populations will outline the need for vigorous control mixed with cultural sensitivity. Contact follow-up, prevention and screening in community and hospital populations will also be discussed. The cases that appear in many of the papers in this series do not represent real patients; each is a composite designed to illustrate a particular situation.

The drafting of this series of articles coincided with the sudden death of Dr. Stefan Grzybowski, one of Canada's greatest contributors to our understanding of TB and its historical and global import. Stefan was born in Poland in 1922. His medical studies in Warsaw were interrupted by the declaration of war, and he subsequently completed his medical degree in Edinburgh and postgraduate pulmonary medicine training in England. He first wrote about TB as a disease of children and adolescents, and that paper led to his recruitment in 1954 to a position in TB control with the government of Ontario. Throughout his life he continued to contribute as a clinician, a teacher and a scientist, writing more about TB epidemiology than anyone else in Canada. He consulted all over the world with endless enthusiasm and

good humour. He worked at a prodigious pace until just weeks before his death on the next article in this series, which relates the history of TB in Canada. Stefan will be sadly missed by his colleagues around the world but especially in Canada. It is to his memory that this series is dedicated.

Competing interests: None declared.

#### References

- Global tuberculosis control, WHO report, 1998. Geneva: World Health Organization; 1998. Available www.who.int/gtb/publications/index.htm Reports (accessed Feb 23, 1999).
- Tuberculosis in Canada, 1995. Ottawa: Health Protection Branch, Health Canada; 1997.
- Grzybowski S, Styblo K, Dorken E. Tuberculosis in Eskimos. Tubercule 1976;57(Suppl):S1-42.
- Stop TB at the source: WHO report on the tuberculosis epidemic, 1995. Geneva: World Health Organization; 1995.
- Hershfield E. The role and tasks of the anti-tuberculosis associations: the Canadian Lung Association and International Health. *Bull Int Union Tuberc Lung Dis* 1987;62:12-6.

**Reprint requests to:** Dr. Anne Fanning, Medical Officer Training, Communicable Disease Prevention and Control, WHO, 20 Avenue Appia, 1211 Geneva 27, Switzerland; fax 44 22 791-4199; fanninga@who.ch